# CYP3A4

## Overview
CYP3A4 is a gene that encodes the enzyme cytochrome P450 family 3 subfamily A member 4, a crucial component of the cytochrome P450 superfamily. This enzyme is primarily found in the liver and small intestine, where it plays a pivotal role in the metabolism of a wide array of xenobiotics and endogenous compounds, including drugs, steroids, and toxins. As a monooxygenase, CYP3A4 catalyzes the oxidation of these substances, facilitating their breakdown and elimination from the body (Li1995Substrates; Guengerich1999CYTOCHROME). The enzyme's large and flexible active site allows it to accommodate diverse substrates, making it a key player in drug metabolism and interactions (Ekroos2006Structural). Variability in CYP3A4 expression and activity, influenced by genetic and environmental factors, can significantly impact drug efficacy and safety, underscoring its clinical importance (Martinez-Jimenez2007Transcriptional; Werk2014Functional).

## Structure
The CYP3A4 protein is a member of the cytochrome P450 superfamily, characterized by its complex molecular structure. The primary structure of CYP3A4 consists of a sequence of amino acids that form the basis for its higher-order structures (Lewis1996Molecular). The secondary structure includes alpha-helices and beta-sheets, which contribute to the protein's stability and function (Williams2004Crystal). The tertiary structure of CYP3A4 forms a compact, globular shape with a heme-binding domain, crucial for its enzymatic activity (Sevrioukova2010Structure). This domain is characterized by a large and adaptable active site, allowing the enzyme to accommodate and metabolize a wide range of substrates (Ekroos2006Structural).

CYP3A4 exhibits significant structural flexibility, with conformational changes observed upon ligand binding, which increases the active site volume and facilitates the binding of multiple ligands simultaneously (Ekroos2006Structural). The protein's quaternary structure involves potential interactions with other proteins, although specific details are not provided in the context. Common post-translational modifications, such as phosphorylation and glycosylation, may occur, influencing the protein's function and stability (Lewis1996Molecular). The structural features of CYP3A4, including its large active site and adaptability, are key to its role in drug metabolism and interactions.

## Function
CYP3A4 is a critical enzyme in the cytochrome P450 family, predominantly expressed in the liver and small intestine, where it plays a significant role in drug metabolism. It is involved in the oxidative metabolism of a wide range of xenobiotics and endogenous compounds, including drugs, steroids, and toxins (Li1995Substrates; Guengerich1999CYTOCHROME). The enzyme catalyzes various reactions such as N-oxidation, C-oxidation, and dealkylation, which facilitate the breakdown and elimination of these compounds from the body (Li1995Substrates).

CYP3A4 is located in the endoplasmic reticulum of cells, particularly in hepatocytes and enterocytes, where it contributes to both pre-systemic and systemic drug metabolism (Watkins1997The; Werk2014Functional). In the small intestine, CYP3A4 is co-localized with P-glycoprotein (Pgp), which suggests a functional integration that affects drug absorption and metabolism (Watkins1997The). This enzyme's activity is subject to significant inter-individual variability due to genetic, environmental, and regulatory factors, impacting drug efficacy and safety (Martinez-Jimenez2007Transcriptional; Werk2014Functional). Understanding CYP3A4's function is crucial for predicting drug interactions and individual responses to pharmacotherapy.

## Clinical Significance
Mutations and alterations in the CYP3A4 gene can significantly impact drug metabolism and are associated with various diseases and conditions. The CYP3A4*1B variant has been linked to prostate cancer progression, particularly in older Caucasian men and African-Americans, and is associated with the transition from benign prostate hypertrophy to prostate cancer (Wojnowski2006Clinical; Wojnowski2004Genetics). This variant is also connected to other conditions, such as altered LDL-cholesterol levels and lung cancer, although findings are inconsistent (Wojnowski2006Clinical).

The CYP3A4*22 variant is associated with decreased enzyme expression, affecting the metabolism of drugs like atorvastatin and tacrolimus, leading to reduced dose requirements (Zanger2013Cytochrome; Werk2014Functional). This variant can alter the pharmacokinetics of several drugs, impacting clinical outcomes (Werk2014Functional).

Alterations in CYP3A4 expression are also linked to cancer progression. Overexpression in malignant tissues is associated with breast and ovarian cancers and may contribute to endometrial cancer initiation (Klyushova2022The). Inflammatory conditions, such as diabetes and rheumatoid arthritis, can suppress CYP3A4 activity, affecting drug metabolism and potentially exacerbating disease states (Klyushova2022The).

## Interactions
CYP3A4 is involved in extensive protein-protein interactions that are crucial for its function in drug metabolism. It forms complexes with other cytochrome P450 enzymes, such as CYP2C9, CYP2E1, and CYP3A5, which can influence its metabolic activity. These interactions can be cooperative or inhibitory, depending on the specific proteins involved and the substrates present (Subramanian2010CYP2C9CYP3A4; Reed2017Physical). 

CYP3A4 also interacts with UDP-glucuronosyltransferase 2B7 (UGT2B7), forming a functional unit known as a "metabolosome." This interaction is facilitated by specific structural regions of CYP3A4, such as the J-helix, which plays a role in binding to UGT2B7 (Takeda2009Interaction; Fujiwara2014Extensive). 

In addition to these interactions, CYP3A4 can form oligomers, including trimeric structures, which are influenced by substrate binding and can affect the enzyme's conformation and activity (Reed2017Physical). The hydrophobic N terminus of CYP3A4 is important for its interaction with other P450 enzymes, and truncation of this region can disrupt these interactions (Subramanian2010CYP2C9CYP3A4). These interactions highlight the complex regulatory mechanisms governing CYP3A4's role in drug metabolism.


## References


[1. (Ekroos2006Structural) Marika Ekroos and Tove Sjögren. Structural basis for ligand promiscuity in cytochrome p450 3a4. Proceedings of the National Academy of Sciences, 103(37):13682–13687, September 2006. URL: http://dx.doi.org/10.1073/pnas.0603236103, doi:10.1073/pnas.0603236103. This article has 647 citations.](https://doi.org/10.1073/pnas.0603236103)

[2. (Sevrioukova2010Structure) Irina F. Sevrioukova and Thomas L. Poulos. Structure and mechanism of the complex between cytochrome p4503a4 and ritonavir. Proceedings of the National Academy of Sciences, 107(43):18422–18427, October 2010. URL: http://dx.doi.org/10.1073/pnas.1010693107, doi:10.1073/pnas.1010693107. This article has 229 citations.](https://doi.org/10.1073/pnas.1010693107)

[3. (Reed2017Physical) James R. Reed and Wayne L. Backes. Physical studies of p450–p450 interactions: predicting quaternary structures of p450 complexes in membranes from their x-ray crystal structures. Frontiers in Pharmacology, January 2017. URL: http://dx.doi.org/10.3389/fphar.2017.00028, doi:10.3389/fphar.2017.00028. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2017.00028)

[4. (Williams2004Crystal) Pamela A. Williams, Jose Cosme, Dijana Matak Vinković, Alison Ward, Hayley C. Angove, Philip J. Day, Clemens Vonrhein, Ian J. Tickle, and Harren Jhoti. Crystal structures of human cytochrome p450 3a4 bound to metyrapone and progesterone. Science, 305(5684):683–686, July 2004. URL: http://dx.doi.org/10.1126/science.1099736, doi:10.1126/science.1099736. This article has 678 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1099736)

[5. (Watkins1997The) P Watkins. The barrier function of cyp3a4 and p-glycoprotein in the small bowel. Advanced Drug Delivery Reviews, 27(2–3):161–170, September 1997. URL: http://dx.doi.org/10.1016/s0169-409x(97)00041-0, doi:10.1016/s0169-409x(97)00041-0. This article has 287 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0169-409x(97)00041-0)

[6. (Li1995Substrates) A Li. Substrates of human hepatic cytochrome p450 3a4. Toxicology, 104(1–3):1–8, December 1995. URL: http://dx.doi.org/10.1016/0300-483x(95)03155-9, doi:10.1016/0300-483x(95)03155-9. This article has 276 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0300-483x(95)03155-9)

[7. (Werk2014Functional) A N Werk and I Cascorbi. Functional gene variants of cyp3a4. Clinical Pharmacology &amp; Therapeutics, 96(3):340–348, June 2014. URL: http://dx.doi.org/10.1038/clpt.2014.129, doi:10.1038/clpt.2014.129. This article has 201 citations.](https://doi.org/10.1038/clpt.2014.129)

[8. (Klyushova2022The) Lyubov S. Klyushova, Maria L. Perepechaeva, and Alevtina Y. Grishanova. The role of cyp3a in health and disease. Biomedicines, 10(11):2686, October 2022. URL: http://dx.doi.org/10.3390/biomedicines10112686, doi:10.3390/biomedicines10112686. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biomedicines10112686)

[9. (Subramanian2010CYP2C9CYP3A4) Murali Subramanian, Harrison Tam, Helen Zheng, and Timothy S. Tracy. Cyp2c9-cyp3a4 protein-protein interactions: role of the hydrophobic n terminus. Drug Metabolism and Disposition, 38(6):1003–1009, March 2010. URL: http://dx.doi.org/10.1124/dmd.109.030155, doi:10.1124/dmd.109.030155. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.109.030155)

[10. (Zanger2013Cytochrome) Ulrich M. Zanger and Matthias Schwab. Cytochrome p450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology &amp; Therapeutics, 138(1):103–141, April 2013. URL: http://dx.doi.org/10.1016/j.pharmthera.2012.12.007, doi:10.1016/j.pharmthera.2012.12.007. This article has 4054 citations.](https://doi.org/10.1016/j.pharmthera.2012.12.007)

[11. (Guengerich1999CYTOCHROME) F. Peter Guengerich. Cytochrome p-450 3a4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39(1):1–17, April 1999. URL: http://dx.doi.org/10.1146/annurev.pharmtox.39.1.1, doi:10.1146/annurev.pharmtox.39.1.1. This article has 979 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1146/annurev.pharmtox.39.1.1)

[12. (Lewis1996Molecular) D. F. V. Lewis, P. J. Eddershaw, P. S. Goldfarb, and M. H. Tarbit. Molecular modelling of cyp3a4 from an alignment with cyp102: identification of key interactions between putative active site residues and cyp3a-specific chemicals. Xenobiotica, 26(10):1067–1086, January 1996. URL: http://dx.doi.org/10.3109/00498259609167423, doi:10.3109/00498259609167423. This article has 63 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/00498259609167423)

[13. (Wojnowski2006Clinical) Leszek Wojnowski and Landry K Kamdem. Clinical implications ofcyp3apolymorphisms. Expert Opinion on Drug Metabolism &amp; Toxicology, 2(2):171–182, March 2006. URL: http://dx.doi.org/10.1517/17425255.2.2.171, doi:10.1517/17425255.2.2.171. This article has 99 citations.](https://doi.org/10.1517/17425255.2.2.171)

[14. (Wojnowski2004Genetics) Leszek Wojnowski. Genetics of the variable expression of cyp3a in humans. Therapeutic Drug Monitoring, 26(2):192–199, April 2004. URL: http://dx.doi.org/10.1097/00007691-200404000-00019, doi:10.1097/00007691-200404000-00019. This article has 100 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/00007691-200404000-00019)

[15. (Martinez-Jimenez2007Transcriptional) Celia Martinez-Jimenez, Ramiro Jover, M. Teresa Donato, Jose Castell, and M. Jose Gomez-Lechon. Transcriptional regulation and expression of cyp3a4 in hepatocytes. Current Drug Metabolism, 8(2):185–194, February 2007. URL: http://dx.doi.org/10.2174/138920007779815986, doi:10.2174/138920007779815986. This article has 172 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/138920007779815986)

[16. (Takeda2009Interaction) Shuso Takeda, Yuji Ishii, Megumi Iwanaga, Arief Nurrochmad, Yuji Ito, Peter I. Mackenzie, Kiyoshi Nagata, Yasushi Yamazoe, Kazuta Oguri, and Hideyuki Yamada. Interaction of cytochrome p450 3a4 and udp-glucuronosyltransferase 2b7: evidence for protein-protein association and possible involvement of cyp3a4 j-helix in the interaction. Molecular Pharmacology, 75(4):956–964, January 2009. URL: http://dx.doi.org/10.1124/mol.108.052001, doi:10.1124/mol.108.052001. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.108.052001)

[17. (Fujiwara2014Extensive) Ryoichi Fujiwara and Tomoo Itoh. Extensive protein interactions involving cytochrome p450 3a4: a possible contributor to the formation of a metabolosome. Pharmacology Research &amp; Perspectives, July 2014. URL: http://dx.doi.org/10.1002/prp2.53, doi:10.1002/prp2.53. This article has 8 citations.](https://doi.org/10.1002/prp2.53)